Education
About Us
Working with TipRanks
Follow Us
Valneva SE (FR:VLA)
:VLA
Earnings Data
Report Date
Nov 13, 2025TBA (Confirmed)
Period Ending
2025 (Q3)Consensus EPS Forecast
-0.14Last Year’s EPS
-0.05Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
Valneva's earnings call highlighted significant revenue growth, strong cash position, and positive progress in vaccine development. However, the company also faced challenges including operating losses and safety concerns for IXCHIQ. The highlights and lowlights were relatively balanced.Company Guidance
Significant Revenue Growth
Valneva achieved total revenues close to EUR 100 million, marking a very significant year-over-year growth. Product sales increased by 33.3% to EUR 91 million compared to EUR 68.3 million in the first half of 2024.
Strong Cash Position
The company reported a cash position of more than EUR 160 million, indicating a strong additional cash influx through ATM transactions and a significant reduction in operating cash burn.
Regulatory and Commercial Achievements
Valneva secured additional marketing authorizations for IXCHIQ in the UK, Brazil, and Europe, and announced an exclusive vaccine marketing and distribution agreement for Germany with CSL Seqirus.
Positive Progress in Vaccine Development
Valneva completed the vaccination in the current VALOR Phase III study for Lyme disease, observed a high sustained 1-year immune response in adolescents for IXCHIQ, and achieved positive Phase III pediatric safety and immunogenicity results for IXCHIQ.
Improved Gross Margin
The gross margin on commercial products, excluding IXCHIQ, increased to 59.2% in the first half of 2025 compared to 47.7% in the prior year.
FR:VLA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
FR:VLA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Aug 12, 2025 | €3.64 | €3.96 | +8.74% |
May 07, 2025 | €2.89 | €2.93 | +1.39% |
Mar 20, 2025 | €3.18 | €3.37 | +5.97% |
Nov 07, 2024 | €2.58 | €2.51 | -2.86% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Valneva SE (FR:VLA) report earnings?
Valneva SE (FR:VLA) is schdueled to report earning on Nov 13, 2025, TBA (Confirmed).
What is Valneva SE (FR:VLA) earnings time?
Valneva SE (FR:VLA) earnings time is at Nov 13, 2025, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Valneva SE stock?
The P/E ratio of Valneva is N/A.
What is FR:VLA EPS forecast?
FR:VLA EPS forecast for the fiscal quarter 2025 (Q3) is -0.14.